Pharmacokinetics of ceftazidime-avibactam in patients receiving continuous renal replacement therapy using a one-compartment pharmacokinetic model and off label dosing regimens
Start Date
April 2026
Location
3rd floor - Library
Abstract
This poster examines the β-lactam antibiotic ceftazidime-avibactam (CAZ-AVI) in critically ill patients receiving continuous renal replacement therapy using a one compartment model with various off-label dosing regimens. β-lactam antibiotic resistance is becoming more common clinical settings, particularly amongst carbapenem-resistant gram-negative bacteria. Patients with acute kidney injury undergoing continuous renal replacement therapy (CRRT) are at risk of drug accumulation or underexposure due to kidney impairment, therefore requiring proactive dosing adjustments. The continuous venovenous hemofiltration (CVVH) modality of renal therapy is more efficient at achieving CAZ-AVI clearance compared to continuous venovenous hemodialysis (CVVHD). Continuous dosing strategy over non-continuous IV infusion better maintains drug concentrations under the toxic threshold while staying above an aggressive PK/PD target.
Pharmacokinetics of ceftazidime-avibactam in patients receiving continuous renal replacement therapy using a one-compartment pharmacokinetic model and off label dosing regimens
3rd floor - Library
This poster examines the β-lactam antibiotic ceftazidime-avibactam (CAZ-AVI) in critically ill patients receiving continuous renal replacement therapy using a one compartment model with various off-label dosing regimens. β-lactam antibiotic resistance is becoming more common clinical settings, particularly amongst carbapenem-resistant gram-negative bacteria. Patients with acute kidney injury undergoing continuous renal replacement therapy (CRRT) are at risk of drug accumulation or underexposure due to kidney impairment, therefore requiring proactive dosing adjustments. The continuous venovenous hemofiltration (CVVH) modality of renal therapy is more efficient at achieving CAZ-AVI clearance compared to continuous venovenous hemodialysis (CVVHD). Continuous dosing strategy over non-continuous IV infusion better maintains drug concentrations under the toxic threshold while staying above an aggressive PK/PD target.
